Amphastar Pharmaceuticals Inc
AMPH
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.1B
Close$
$69.37
168.1% upside
Current Fair Value
168.1% upsideUndervalued by 168.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.10 Billion |
|---|---|
| Enterprise Value | $1.57 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.1 |
| Beta | 0.9 |
| Outstanding Shares | 43,644,000 |
Return
| Return on Equity | 10.23% |
|---|---|
| Return on Assets | 4.50% |
| Return on Invested Capital | 8.29% |
Valuation & Multiples
| P/E Ratio | 14.87 |
|---|---|
| PEG | -676.46 |
| Price to Sales | 1.62 |
| Price to Book Ratio | 1.52 |
| Enterprise Value to Revenue | 2.15 |
| Enterprise Value to EBIT | 12.78 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | 0.9 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.62
Average shareholder expectationRevenue Estimate
$179.92 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.86
Average shareholder expectationRevenue Estimate
$197.85 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 46.85% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.20%▼ 62.98% |
|---|---|
| Total Invested | $2.28M▼ 99.60% |
| Investors Holding | 17▼ 198.00% |
ESG Score
No data
About Amphastar Pharmaceuticals Inc
CEO: Jack Zhang